`
`
`(19) United States
`
`
`
`
`
`
`
`
`
`(12) Patent Application Publication (10) Pub. No.: US 2012/0022157 A1
`
`
`
`
`
`
`
`Scharschmidt
`(43) Pub. Date:
`Jan. 26, 2012
`
`US 20120022157A1
`
`
`
`
`(54) DOSING AND MONITORING PATIENTS ON
`
`
`
`
`
`NITROGEN-SCAVENGING DRUGS
`
`
`
`(75)
`
`
`Inventor:
`
`
`
`(73) Assignee:
`
`
`
`Bruce Scharschmidt, South San
`
`
`
`
`
`
`
`Francisco, CA (US)
`
`
`
`
`UCYCLYD PHARMA, INC,
`Scottsdale, AZ (US)
`
`
`(21) Appl. No.:
`
`
`
`
`13/061,509
`
`
`Publication Classification
`
`
`
`
`(51)
`
`
`
`Int. Cl.
`
`
`AHK 31/216
`
`
`
`A61P 3/00
`G01N 33/00
`
`
`
`
`A611’ 13/12
`
`
`
`(200601)
`(2006.01)
`(2006.01)
`(200501)
`
`
`
`
`
`
`(52) U.S. Cl. ....................... .. 514/533; 514/532; 73/61.41
`
`
`
`
`
`
`
`
`
`
`
`(22) PCT Filed:
`
`
`
`
`
`Aug. 27, 2009
`
`
`
`(57)
`
`
`
`ABSTRACT
`
`
`
`
`
`(86) PCT No,;
`
`
`
`PCT/US09/55256
`
`
`
`§ 371 (c)(l),
`
`
`
`(2), (4) Date:
`
`
`
`
`Jun. 15, 2011
`
`
`
`
`
`
`
`
`
`Related U-S- Application Data
`
`
`
`
`
`
`(63) Continuation-in-part of application No. PCT/US09/
`
`
`
`
`
`30362, filed on Jan. 7, 2009, Continuation-in-part of
`
`
`
`
`
`
`
`application No. 12/350,111, filed on Jan. 7, 2009.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`(60) Provisional application No, 61/093,234, filed on Aug,
`
`
`
`
`
`
`29, 2008, provisional application No. 61/093,234,
`filed on Aug, 29, 2008,
`
`
`
`
`
`
`
`
`
`
`
`
`The invention provides a method for determining a dose and
`dosing schedule, and making dose adjustments of patients
`
`
`
`
`
`
`
`
`taking PBA prodrugs as nitrogen scavengers to treat nitrogen
`
`
`
`
`
`
`
`retention states, including ammonia accumulation disorders
`
`
`
`
`
`
`as well as chronic renal failure, by measuring urinary excre-
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`tion of phenylacetylglutarnine and/or total urinary nitrogen.
`The invention provides methods to select an appropriate dos-
`
`
`
`
`
`
`
`age of a PBA prodrug based on the patient’s dietary protein
`
`
`
`
`
`
`
`intake, or based on previous treatments administered to the
`
`
`
`
`
`
`
`patient. The methods are applicable to selecting or modifying
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`a dosing regimen for a subject receiving an orally adminis-
`
`
`
`
`
`
`
`tefed Waste nitrogen scavenging dmg, and 10 monitoring
`
`
`
`
`patients receiving such drugs.
`
`Page 1 of 48
`
`Horizon Exhibit 2012
`
`Lupin V. Horizon
`IPR2016-00829
`
`Page 1 of 48
`
`Horizon Exhibit 2012
`Lupin v. Horizon
`IPR2016-00829
`
`
`
`
`
`Patent Application Publication
`
`
`
`
`
`
`
`Jan. 26, 2012 Sheet 1 of 17
`
`
`
`US 2012/0022157 A1
`
`
`
`..n..._m_.._.._D..u4__m._._n.5_.._
`
`
`
`
`
`_mEmecozu§8E__o:§_.s.,&
`.Em§oaas__§£
`
`
`
`
`
`.2ouswwm
`
`
`sé5.5.
`
`
`
`
`3522gxer222$
`
`
`
`539m.ram
`
`
`
`
`2.2635
`
`
`
`
`
`Cm>_.:mEoEE<
`
`Baas
`
`
`
`
`
`
`
`
`
`
`
`Emae=__.mu__E_amu__::__uE5.33%.§.._._E8E._u._§_=E<
`
`
`
`
`
`
`
`
`
`
`
`
`
`Eaanus.r_2__§m:ussm55:23.552:2fies:
`
`
`
`
`
`Page 2 of 48
`
`Page 2 of 48
`
`
`
`
`
`
`
`
`Patent Application Publication
`
`
`
`
`
`
`
`Jan. 26, 2012 Sheet 2 of 17
`
`
`
`US 2012/0022157 A1
`
`
`
`Sodium Phenlybutyrate
`
`
`J,
`Phenylacefate
`
`
`\(
`
`| PhenylacetyIg|utamine|
`
`v
`.
`.
`
`
`Um“? EXCVWO"
`:fi A
`
`
`
`1/
`
`
`
`
`
`
`
`
`*”
`
`
`
`
`
`
`
`
`
`
`
`I
`
`
`
`
`J1--1’
`
`
`
`
`Argininosuccinates *’
`
`
`
`
`_
`‘
`
`
`Supplemented/2 A’9'”‘”e
`.
`
`
`
`
`Fumarate
`Arginine
`
`ASL
`
`
`
`
`Figure lb
`
`Page 3 of 48
`
`
`
`NH+ 4
`—Katoglu*:arate
`NH+4 ¥-+ G|utamate—$—-—> Glutamine
`
`
`
`
`
`A'‘‘P
`
`[Q"p'_§}
`
`H003
`
`
`
`
`
`
`Carbamyl Phosphate
`
`
`
`Page 3 of 48
`
`
`
`
`
`E=e9a_mm
`
`
`
`
`:§=8_83%u_E3m.$ms523¢9.E;2«mmB=2m§=8Emzazm28E582.:
`
`
`
`=w&=;_s_.§§.§_._S.5255.95...
`
`.___.§:._._¢_m___._Eu_=_8.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Patent Application Publication
`
`
`
`Jan. 26, 2012 Sheet 3 of 17
`
`US 2012/0022157 A1
`
`
`
`
`
`
`
`3?:29:
`
`
`
`L’?
`SE:) .
`
`N3:3
`
`
`
`
`
`9;:c_n_>5%.NE>.:2>x2.E3
`
`
`
`
`
`2%Ema___em__m_.ao_m_.EmE:8.E8mews...
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`«Emma2_£uE_u2222mezmmm2Spam
`
`
`
`
`
`Emetmqeoo.8259memmi
`
`mE_§E8__8a__o%_mE
`
`
`
`2298
`
`Page 4 of 48
`
`Page 4 of 48
`
`
`
`
`
`
`
`Patent Application Publication
`
`
`
`Jan. 26, 2012 Sheet 4 of 17
`
`
`
`US 2012/0022157 A1
`
`
`
`
`
`mEzwwm
`
`
`
`
`
`
`
`
`#%%m%mmflflwQH@¥5¥w¥¥mz?,V*s¥mx*¢fia-:«mx*¢W_.§=..a-.....i
`aszofiumm___
`%Nmx%-mm¥
`_$nwwnnnwnnnnnuunuwnuunnununmnuunnnnuwJ
`
`...................................-%£Emm%mMm¢mwEM mWmAEa§Eex525;wxflaaémm
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`oo_-z¢:_oea=m;a:m
`
`
`wmoa
`
`
`
`Page 5 of 48
`
`Page 5 of 48
`
`
`
`
`
`
`
`
`Patent Application Publication
`
`
`
`
`
`
`
`Jan. 26, 2012 Sheet 5 of 17
`
`
`
`US 2012/0022157 A1
`
`
`BuphenyI®(3g/m2)
`
`
`5000
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`MeanPlasmaEancentration(uM)
`
`lJon_centralinn(uM)
`
`MeanPlasma
`
`
`
`
`0
`
`
`
`5
`
`
`
`25
`
`30
`
`10
`
`15
`
`
`20
`
`
`
`Time (Hours)
`HPN-100(3g/m2)
`
`
`
`5000-
`
`500
`
`
`Time (Hours)
`
`
`
`
`Figure 4
`
`Page 6 of 48
`
`Page 6 of 48
`
`
`
`
`
`
`Patent Application Publication
`
`
`
`
`
`Jan. 26, 2012 Sheet 6 of 17
`
`
`
`US 2012/0022157 A1
`
`
`mu..=wE
`
`
`
`.2225_m9:uuse.2§____:652
`
`
`
`
`me.$22.382:89_a$.§mcmmga
`
`=o_§8Eu_E2m.$m5358.9%
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`2%E53>__~:_£.m_a___n_2_§~o_m
`
`u_E2m.$2535E9...2%E:9%.5
`
`m_%__.§Sm_n.:EEesmmm
`mum.=o__H.m__§_u
`
`
`Page 7 of 48
`
`Page 7 of 48
`
`
`
`
`
`
`
`
`Patent Application Publication
`
`
`
`
`
`
`
`Jan. 26, 2012 Sheet 7 of 17
`
`
`
`US 2012/0022157 A1
`
`UP1204~00:l.: Blood Metabolite Concentrations
`
`
`
`
`
`
`
`
`Vs. Time in Healthy Adults*
`
`
`
`
`
`Analyle= PBA
`
`
`
`
`
`
`
`
`
`
`* Shows BID dosing from days 8-15.
`
`
`
`
`
`
`Plasma PBA levels returned to near predose
`level between doses on each day during
`
`
`
`
`
`
`
`
`
`
`
`multiple dosing for healthy individuals.
`.
`
`
`
`
`
`
`PAA levels increase, but reach a steady-
`
`
`
`
`
`state after 3 days of BID dosing
`
`
`
`
`
`‘J G G
`
`E 50
`
`
`5
`
`,=
`
`L5.
`
`
`§3
`
`
`= 35
`
`=
`-1
`
`
`10
`
`
`5
`
`
`
`
`
`
`
`200
`
`
`
`300
`
`I 350
`
`
`
`250
`Time (Hours)
`
`
`
`
`400
`
`Analyle=PAGN
`
`
`
`100
`
`
`
`:3
`
`
`
`
`
`5 so
`E
`O.
`
`
`.5
`
`
`’a‘
`
`E
`
`
`EL 10-
`=
`
`
`E.
`
`
`E 5
`=
`_l
`
`
`
`
`
`Analyle=l-“AA
`
`’
`
`250
`
`300
`
`
`
`
`Time (Hours)
`
`350
`
`
`
`400
`
`
`
`200
`
`
`
`
`
`
`Figure 6
`
`250
`
`300
`
`350
`
`
`
`
`Time (Hours)
`
`
`
`
`
`400
`
`
`
`100
`
`M
`
`
`5 so
`2
`D.
`
`
`.'.=.
`
`
`6
`
`.%
`
`
`E.
`10
`::
`
`
`E
`
`
`E 5
`E
`..J
`
`
`
`200
`
`
`
`Page 8 of 48
`
`Page 8 of 48
`
`
`
`
`
`
`Patent Application Publication
`
`
`
`
`
`Jan. 26, 2012 Sheet 8 of 17
`
`
`
`US 2012/0022157 A1
`
`
`
`UP1204—U0:§‘: Blood lvletabolite Concentrations
`
`Vs. Time in Palients With Cirrhosis (Childs-Pugh C)
`
`Analvte=Pl3A
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`* Shows BID dosing from days 8-15.
`
`
`
`
`
`Plasma PBA levels returned to near predose
`
`
`
`
`
`
`level between doses on each day during
`
`
`
`
`
`mulljple dosing in cirrhotics. PAA levels
`
`
`
`
`
`
`increase and require 4 days to reach
`
`
`
`
`
`steady-state with BID dosing
`
`
`
`
`
`
`
`
`
`LnMean{uMm2)inPlasma
`
`200
`
`
`
`~
`% 100
`:2
`D.
`
`-E 50
`7-3.?
`
`E
`E
`E’ 10-
`E
`5 5
`
`
`
`
`
`
`
`250
`
`
`‘350
`300
`
`
`Time (Hours)
`
`
`
`400
`
`
`
`Analyle-—=PAGN
`
`
`
`
`Analyte=PAA
`zen
`
`~
`E 100
`:2
`D.
`
`E 50
`RT
`E
`=?=.
`E’
`E
`5 5-
`
`10
`
`200
`
`
`
`
`
`250
`300
`350
`
`
`Time (Hours)
`
`400
`
`
`
`200
`
`
`
`
`Figure7
`
`25[l
`300
`350
`
`
`
`Time (Hours)
`
`
`
`400
`
`
`
`Page 9 of 48
`
`Page 9 of 48
`
`
`
`
`
`
`Patent Application Publication
`
`
`
`
`
`Jan. 26, 2012 Sheet 9 of 17
`
`
`
`US 2012/0022157 A1
`
`
`
`
`
`
`
`PBA. cmax and AUC and HPN Dose
`
`
`
`
`
`
`200
`
`
`
`
`
`50
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`150
`
`
`
`u
`
`
`100 3
`
`
`
`
`
`
`
`
`
`
`
`HPNDose
`
`
`HPN Dose
`
`
`
`
`
`
`
`
`PBA AUC and HPN Dose
`
`
`-0- PBA Auc0—24
`-A— Cmaxss
`
`
`
`
`—E|— HPN Dose
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Cmax
`
`
`
`Page 10 of 48
`
`Page 10 of 48
`
`
`
`
`
`
`Patent Application Publication
`
`
`
`
`
`Jan. 26, 2012 Sheet 10 of 17
`
`
`
`US 2012/0022157 A1
`
`
`
`
`
`PAA AUC and HPN Dose
`'
`—£}— HPN-100
`
`
`
`
`3500
`
`
`
`20
`
`
`
`15
`
`
`
`
`10
`
`5
`
`
`0
`
`
`Page 11 of 48
`
`
`
`
`
`
`
`
`
`-3000
`
`
`
`2500
`
`
`
`2000
`
`
`
`
`
`1500
`
`1000
`
`500
`
`
`
`0
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Figure 8b
`
`Page 11 of 48
`
`
`
`
`
`Patent Application Publication
`
`
`
`
`
`
`
`Jan. 26, 2012 Sheet 11 of 17
`
`
`
`US 2012/0022157 A1
`
`‘U-PAGN and HPN Dose
`
`
`
`
`
`
`
`
`20-
`D HPN_PBA 10000000
`13
`°'“'PAGN -14000000
`
`
`
`
`
`
`
`12000000
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`10000000
`
`8000000
`
`6000000
`
`
`
`
`
`4000000
`
`2000000
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`0
`
`
`
`
`
`Page 12 of 48
`
`Page 12 of 48
`
`
`
`
`
`Patent Application Publication
`
`
`
`
`
`
`
`Jan. 26, 2012 Sheet 12 of 17
`
`
`
`US 2012/0022157 A1
`
`
`
`
`
`
`
`
`
`
`
`
`TNAUC(pIVI)
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`TN-Auc
`
`BUPHENYL® HPN-100
`
`
`
`
`—-— Mean
`
`—-- Median
`
`
`
`
`%
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Cmax
`
`E»'UPHENYL® HPN-100
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`NH3(pmoI/L)
`
`
`
`
`
`
`
`
`NH3(pmoI/L}
`
`
`
`
`
`
`
`
`
`
`
`BUPl;iENYL®
`
`
`
`
`38.4 :+-/- 19.6
`
`
`
`79.1 ‘+/- 40.1
`
`HPN—1oo
`
`
`
`26.1 +/- 10.3
`
`
`56.3 +/- 27.9
`
`
`
`
`
`
`
`Figure 9
`
`Page 13 of 48
`
`Page 13 of 48
`
`
`
`
`
`
`Patent Application Publication
`
`
`
`
`
`Jan. 26, 2012 Sheet 13 of 17
`
`
`
`US 2012/0022157 A1
`
`
`
`
`Cumulative Ammonia Concentration TN-AUG
`
`
`—z2——HPN
`—E.‘_l—BUP
`
`
`
`’
`
`5%
`
`12-24H!‘
`
`
`Figurelfl
`
`
`
`_’
`
`”/A
`
`
`
`3x
`
`
`U-12H!‘
`
`
`
`
`
`
`1:
`.2
`
`Page 14 of 48
`
`Page 14 of 48
`
`
`
`
`
`Patent Application Publication
`
`
`
`
`
`
`
`Jan. 26, 2012 Sheet 14 of 17
`
`
`
`US 2012/0022157 A1
`
`:fiaua
`
`
`
`
`
`
`
`
`%,;_:,_$_o:<2_.¢:m_
`
`
`
`FEHE82
`E2Se53
`:2SE52
`3;.SE32
`SE5.2.8.:
`
`
`
`
`E8=,_n_T_=n5aE_e_m
`
`
`
`Page 15 of 48
`
`E232;.38LT
`
`
`
`32:3%asnu.
`
`SE.3:Newin
`:2:23%11
`SESE88I?
`
`
`
`
`Page 15 of 48
`
`
`
`
`
`
`
`
`Patent Application Publication
`
`
`
`
`
`Jan. 26, 2012 Sheet 15 of 17
`
`
`
`US 2012/0022157 A1
`
`
`
`
`Ammonia(T|‘.I-AUG) After 7 Days of Treatment
`
`
`
`
`with BUPHENYI? and HPN-100
`
`
`
`
`80~
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`HPN-100
`
`
`
`
`
`Mean
`
`
`
`26.1+/~1D.3
`
`
`
`
`
`E: 60
`
`
`
`O E E
`
`.
`.2 40
`
`
`E 20_
`
`
`E E
`
`HPN-100
`
`
`
`
`
`. B
`
`
`
`
`UPHENYL®
`
`D
`
`
`
`L Figure 12
`
`
`
`Page 16 of 48
`
`Page 16 of 48
`
`
`
`
`
`
`Patent Application Publication
`
`
`
`
`
`Jan. 26, 2012 Sheet 16 of 17
`
`
`
`US 2012/0022157 A1
`
`C’!5
`
`I__'_
`5
`
`
`
`
`
`
`“ml anvm
`
`
`
`Page 17 of 48
`
`Page 17 of 48
`
`
`
`
`
`
`Patent Application Publication
`
`
`
`
`
`Jan. 26, 2012 Sheet 17 of 17
`
`
`
`US 2012/0022157 A1
`
`
`
`emacmmEauom.sH§m_
`
`
`$5EaumcoS_E§=_E3.
`
`
`
`«E5595.3:2:%§_2
`
`
`
`
`
`
`
`$2Eaé§__§_.25.5.1EE2.so:
`
`meme2\mamam
`
`
`
`\msmau.m
`
`22:E:
`
`32:3
`
`
`
`
`
`
`
`E:
`
`
`
`2;
`
`
`
`as
`
`
`
`2.
`
`Page 18 of 48
`
`Page 18 of 48
`
`
`
`
`
`
`US 2012/0022157 Al
`
`
`
`Jan. 26, 2012
`
`
`
`DOSING AND MONITORING PATIENTS ON
`
`
`
`
`NITROGEN-SCAVENGING DRUGS
`
`
`
`CROSS-REFERENCE TO RELATED
`
`
`APPLICATIONS
`
`
`[0001] This application is a continuation in part of U.S.
`
`
`
`
`
`
`
`Nonprovisional patent application Ser. No. 12/350,111, filed
`
`
`
`
`
`
`
`Jan. 7, 2009 which is pending, and a continuation in part of
`
`
`
`
`
`
`
`International Application No. PCT/US08/303 62, filed Jan. 9,
`
`
`
`
`
`
`
`
`2009, each of which claims benefit of priority to U.S. Provi-
`
`
`
`
`
`
`
`
`sional Application Ser. No. 61/093,234, filed Aug. 29, 2008,
`
`
`
`
`
`
`
`
`
`each of which is incorporated herein by reference in its
`
`
`
`
`
`
`
`
`
`entirety. This application is also related to the U.S. provi-
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`sional patent application entitled “Treating special popula-
`tions having liver disease with nitrogen-scavenging com-
`
`
`
`
`
`
`
`pounds,” naming Sharron Gargosky as inventor, Ser. No.
`
`
`
`
`
`
`
`61/048,830, filed on Apr. 29, 2008.
`
`
`
`
`
`TECHNICAL FIELD
`
`
`
`[0002] This invention relates to treatment of patients with
`
`
`
`
`
`
`
`nitrogen retention states,
`including urea cycle disorders
`
`
`
`
`
`
`
`
`
`
`
`
`(UCDs), cirrhosis complicated by hepatic encephalopathy
`(HE) and chronic renal failure (CRF), using administered
`
`
`
`
`
`
`
`
`compounds that assist in elimination of waste nitrogen from
`
`
`
`
`
`
`
`the body. The compounds can be orally administered small-
`
`
`
`
`
`
`
`
`molecule drugs, and the invention provides methods for
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`delivering such compounds and selecting suitable dosages for
`a patient as well as adjusting dosages and monitoring effec-
`
`
`
`
`
`
`
`
`tiveness of a treatment. As depicted in FIG. 1a, inherited
`
`
`
`
`
`
`
`
`disorders (e.g., UCDs) and acquired disorders (e.g. cirrhosis,
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`typically with portal systemic shunting, complicated by HE)
`involving the liver which impair the normally efiicient clear-
`
`
`
`
`
`
`
`
`
`ance of ammonia from the portal circulation and conversion
`
`
`
`
`
`
`
`
`to urea via the urea cycle, depicted in FIG. 1b, result in
`
`
`
`
`
`
`
`
`
`
`
`elevated levels in the blood of ammonia, a potent neurotoxin.
`
`
`
`
`
`
`
`CRF, while associated in some instances with mildly elevated
`
`
`
`
`
`
`
`
`levels ofammonia, (Deferrari, Kidlnl. 1980; 20:505), results
`
`
`
`
`
`
`
`in retention of other nitrogenous waste products normally
`
`
`
`
`
`
`
`
`excreted in the urine, in particular urea, the blood levels of
`
`
`
`
`
`
`
`
`
`
`which are commonly used to assess renal function.
`
`
`
`
`
`
`[0003] Restriction of dietary protein (i.e. intake of dietary
`
`
`
`
`
`
`
`nitrogen) is commonly used in the management of each of
`
`
`
`
`
`
`these nitrogen retention states, to avoid accumulation of
`
`
`
`
`
`
`
`
`ammonia or metabolic products containing ammonia, e.g.,
`
`
`
`
`
`
`urea. References herein to ammonia and ammonia scaveng-
`
`
`
`
`
`
`
`ing refer primarily to treating UCDs and HE and conditions
`
`
`
`
`
`
`that emulate UCDs, although the terms ammonia scavenging
`
`
`
`
`
`
`
`
`and waste nitrogen scavenging are used interchangeably.
`
`
`
`
`
`
`
`
`BACKGROUND ART
`
`
`
`[0004] Drug dosing is usually based upon measurement of
`
`
`
`
`
`
`
`blood levels of the active drug species in conjunction with
`
`
`
`
`
`
`
`
`
`the
`clinical assessment of treatment response. However,
`
`
`
`
`
`
`
`present invention is based on evidence that for certain pro-
`
`
`
`
`
`
`
`
`drugs of phenylacetic acid (PAA), measuring the blood level
`
`
`
`
`
`
`
`
`of the prodrug (e.g. PBA) or of PAA formed from it is unre-
`
`
`
`
`
`
`
`
`
`liable in assessing drug effect: drug levels in the blood do not
`
`
`
`
`
`
`
`
`
`correlate with efiicacy in this case. In addition, assessment of
`
`
`
`
`
`
`
`treatment effect by measuring levels of ammonia in the blood
`
`
`
`
`
`
`
`in UCD patients is also potentially unreliable. Individual
`
`
`
`
`
`
`
`ammonia level measurements vary several-fold over the
`
`
`
`
`
`
`
`course of a day for a given patient, and withdrawing multiple
`
`
`
`
`
`
`
`
`blood samples under carefully controlled conditions over an
`
`
`
`
`
`
`
`
`Page 19 of 48
`
`extended period of time is clinically impractical as a way to
`
`
`
`
`
`
`monitor a treated patient. The variability in blood ammonia
`
`
`
`
`
`
`
`levels reflects the fact that ammonia levels in UCD patients
`
`
`
`
`
`
`
`
`
`are affected by various factors including dietary protein and
`
`
`
`
`
`
`
`
`timing in relation to meals, such that any individual value fails
`
`
`
`
`
`
`
`
`
`to provide a reliable measure of how much ammonia the drug
`
`
`
`
`
`
`
`
`is mobilizing for elimination; i.e. drug effect. The invention
`
`
`
`
`
`
`
`
`
`demonstrates that prodrugs of phenylbutyric acid (PBA)
`
`
`
`
`
`
`
`behave similarly to sodium PBA, in that measuring PBA
`
`
`
`
`
`
`
`
`levels is unreliable for assessing their effectiveness. This
`
`
`
`
`
`
`
`
`invention provides a novel method for dosing in patients with
`
`
`
`
`
`
`
`nitrogen retention states, in particular patients with liver dis-
`
`
`
`
`
`
`
`
`ease and clinical manifestations of hepatic encephalopathy
`
`
`
`
`
`
`and patients with UCDs. It is particularly applicable to pro-
`
`
`
`
`
`
`
`drugs that liberate or are metabolized to form phenylacetic
`
`
`
`
`
`
`
`
`i.e., prodrugs of PAA, and those prodrugs that are
`acid,
`
`
`
`
`
`
`
`
`
`
`metabolized to form PBA.
`
`
`
`[0005] Hepatic encephalopathy (HE) refers to a reversible
`
`
`
`
`
`
`spectrum ofneurologic signs and symptoms which frequently
`
`
`
`
`
`
`
`occur in patients with cirrhosis or certain other types of liver
`
`
`
`
`
`
`
`
`disease.
`
`[0006] Urea cycle disorders (UCDs) comprise several
`
`
`
`
`
`
`
`
`inherited deficiencies of enzymes or transporters necessary
`
`
`
`
`
`for the synthesis of urea from ammonia. The urea cycle is
`
`
`
`
`
`
`
`
`
`
`depicted in FIG. 1b, which also illustrates how certain ammo-
`
`
`
`
`
`
`
`
`
`nia-scavenging drugs act to assist in elimination of excessive
`
`
`
`
`
`
`ammonia. UCDs include inherited conditions associated with
`
`
`
`
`
`
`
`insufficient function of any one of several an1rnonia-process-
`
`
`
`
`
`
`ing enzymes. Individuals born with no meaningful residual
`
`
`
`
`
`
`
`urea synthetic capacity typically present in the first few days
`
`
`
`
`
`
`
`
`
`oflife (neonatal presentation). Individuals with residual func-
`
`
`
`
`
`
`
`
`tion typically present later in childhood or even in adulthood,
`
`
`
`
`
`
`
`and symptoms may be precipitated by increased dietary pro-
`
`
`
`
`
`
`
`tein or physiological stress (e.g. intercurrent illness.) Some
`
`
`
`
`
`
`
`enzymes whose deficient functioning causes UCDs include
`
`
`
`
`
`
`
`the following:
`
`
`
`
`
`
`[0007] Carbamyl phosphate synthetase (CPS),
`ornithine transcarbamylase (OTC),
`[0008]
`
`
`
`
`
`
`
`argininosuccinate synthetase (ASS),
`[0009]
`
`
`
`
`argininosuccinate lyase (ASL),
`[0010]
`arginase (ARG; EC Number 3.5.3.1; autosomal
`[0011]
`
`
`
`
`
`recessive), (ARG) and
`
`
`
`
`
`
`
`
`[0012] N-acetyl glutamine synthetase (NAGS)
`[0013] Mitochondrial transporter deficiency states which
`
`
`
`
`
`mimic many features of urea cycle enzyme deficiencies, and
`
`
`
`
`
`
`
`thus emulate UCDs and are treatable by the methods
`
`
`
`
`
`
`
`
`described herein for treating UCDs, include the following:
`
`
`
`
`
`
`
`
`[0014] Omithine translocase deficiency (hyperorni-
`
`
`
`
`
`thinemia, hyperamrnonemia, homocitrullinuria or HHH
`
`
`
`
`
`Syndrome)
`[0015] Citrin (aspartate glutamate transporter) defi-
`
`
`
`
`
`
`
`ciency
`[0016] The common feature of UCDs and similar condi-
`
`
`
`
`
`
`
`
`tions and hepatic encephalopathy that render them treatable
`
`
`
`
`
`
`
`
`by methods of the invention is an accumulation of excess
`
`
`
`
`
`
`
`waste nitrogen in the body, and hyperammonemia. CRF is
`
`
`
`
`
`
`
`similarly characterized by build-up of excessive waste nitro-
`
`
`
`
`
`
`gen in the blood in the form urea, and the ammonia scaveng-
`
`
`
`
`
`
`
`
`
`ing drugs described herein are likewise effective to prevent
`
`
`
`
`
`
`
`
`accumulation of excess levels of urea. In normal individuals,
`
`
`
`
`
`
`the body’s intrinsic capacity for waste nitrogen excretion is
`
`
`
`
`
`
`
`
`greater than the body’s waste nitrogen production, so waste
`
`
`
`
`
`
`
`
`nitrogen does not accumulate and ammonia does not build up
`
`
`
`
`
`
`
`
`
`to harmful levels. For patients with nitrogen retention states
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Page 19 of 48
`
`
`
`
`
`US 2012/0022157 A1
`
`
`
`Jan. 26, 2012
`
`
`
`such as UCD or HE, the body’s intrinsic capacity for waste
`
`
`
`
`
`
`
`
`
`nitrogen excretion is less than the body’s waste nitrogen
`
`
`
`
`
`
`
`
`production based on a normal diet that contains significant
`
`
`
`
`
`
`
`amounts ofprotein. As a result, waste nitrogen builds up in the
`
`
`
`
`
`
`
`body of a patient having a nitrogen retention disorder, which
`
`
`
`
`
`
`
`usually results in excess ammonia in the blood. This has
`
`
`
`
`
`
`
`
`
`various toxic effects; drugs that help eliminate the excess
`
`
`
`
`
`
`
`
`
`ammonia are an important part of an overall management
`
`
`
`
`
`
`
`
`strategy for such disorders.
`
`
`
`
`To avoid build-up of ammonia to toxic levels in
`[0017]
`
`
`
`
`
`
`
`
`
`patients with nitrogen retention states, dietary intake of pro-
`
`
`
`
`
`
`
`
`tein (a primary source of exogenous waste nitrogen) must be
`
`
`
`
`
`
`
`balanced by the patient’s ability to eliminate excess ammonia.
`
`
`
`
`
`
`Dietary protein can be limited, but a healthy diet requires
`
`
`
`
`
`
`
`
`sufficient protein to support normal growth (i.e. in growing
`
`
`
`
`
`
`
`
`children) and repair; thus in addition to controlling dietary
`
`
`
`
`
`
`
`protein intake, drugs that assist with elimination of nitrogen
`
`
`
`
`
`
`
`
`are used to reduce ammonia build-up (hyperamrnonemia).
`
`
`
`
`
`
`The capacity to eliminate excess ammonia in treated patients
`
`
`
`
`
`
`
`can be considered the sum ofthe patient’s endogenous capac-
`
`
`
`
`
`
`
`ity for nitrogen elimination (if any) plus the amount of addi-
`
`
`
`
`
`
`
`
`
`
`tional nitrogen-elimination capacity that is provided by a
`
`
`
`
`
`nitrogen scavenging drug. The methods ofthe invention use a
`
`
`
`
`
`
`
`variety of different drugs that reduce excess waste nitrogen
`
`
`
`
`
`
`
`
`and ammonia by converting it to readily-excreted forms, such
`
`
`
`
`
`
`as phenylacetyl glutamine (PAGN). In some embodiments,
`
`
`
`
`
`
`the invention relates to methods for determining or adjusting
`
`
`
`
`
`
`a dosage of an oral drug that forms PAA in vivo, which is
`
`
`
`
`
`
`
`
`
`converted into PAGN, which is then excreted in urine and thus
`
`
`
`
`
`
`
`
`
`helps eliminate excess nitrogen.
`
`
`
`
`[0018] Based on prior studies in individual UCD patients
`
`
`
`
`
`
`
`(e.g. Brusilow, Pediatric Research, vol. 29, 147-50 (1991);
`
`
`
`
`
`
`
`
`Brusilow and Finkelstien, .1. Metabolism, vol. 42, 1336-39
`
`
`
`
`
`
`
`(1993)) in which 80-90% of the nitrogen scavenger sodium
`
`
`
`
`
`
`
`phenylbutyrate (a PAA prodrug) was reportedly excreted in
`
`
`
`
`
`
`the urine as PAGN, current treatment guidelines typically
`
`
`
`
`
`
`
`
`either assume complete conversion of sodium phenylbutyrate
`
`
`
`
`
`
`or other PAA prodrugs to PAGN (e.g. Berry et al., .1. Pediat-
`
`
`
`
`
`
`
`
`
`
`rics, vol. 138, S56-S61 (2001)) or do not comment on the
`
`
`
`
`
`
`
`
`
`implications of incomplete conversion for dosing (e.g. Singh,
`
`
`
`
`
`
`Urea Cycle Disorders Conference Group ‘Consensus State-
`
`
`
`
`
`
`
`mentfrom a Conferencefor the Management ofPatients with
`
`
`
`
`
`
`Urea Cycle Disorders’, Suppl to JPediatrics, vol. 138(1),
`
`
`
`
`
`
`
`S1-S5 (2001)). Based on what is known, one expects essen-
`
`
`
`
`
`
`
`
`tially complete conversion of these drugs into urinary PAGN.
`
`
`
`
`
`
`
`
`[0019]
`PBA is currently the preferred nitrogen scavenging
`
`
`
`
`
`
`
`drug for UCD patients in need of substantial nitrogen elimi-
`
`
`
`
`
`
`
`
`nation capacity. Current treatment guidelines recommend 4
`
`
`
`
`
`
`times per day dosing with PBA, based on the fact that PBA is
`
`
`
`
`
`
`
`
`
`
`absorbed rapidly from the intestine when administered in the
`
`
`
`
`
`
`
`
`form of sodium PBA and exhibits a short half life in the
`
`
`
`
`
`
`
`
`
`bloodstream (Urea Cycle Disorders Conference Group ‘Con-
`
`
`
`
`
`
`
`sensus Statement’ 2001). Current
`recommendations for
`
`
`
`
`
`
`sodium phenylbutyrate dosing in UCD patients indicate that
`
`
`
`
`
`
`
`dosage should not exceed 600 mg/kg (for patients weighing
`
`
`
`
`
`
`
`
`
`up to 20 kg) or in any case 20 gran1s total per day. Frequent
`
`
`
`
`
`
`
`
`
`dosing helps minimize the peak levels of ammonia, which can
`
`
`
`
`
`
`
`
`be very harmful, and it minimizes buildup of high concentra-
`
`
`
`
`
`
`
`
`tions of PAA as well.
`
`
`
`[0020] CRF (chronic renal failure) resulting from a variety
`
`
`
`
`
`
`
`
`of causes (e.g. diabetes, hypertension, glomerular disease,
`
`
`
`
`
`
`
`etc.) is associated with diminished excretion from the body of
`
`
`
`
`
`
`
`water soluble waste products normally present in the urine,
`
`
`
`
`
`
`
`
`including nitrogenous waste such as urea. While the contri-
`
`
`
`
`
`
`
`
`
`Page 20 of 48
`
`bution of increased blood levels of urea, per se, to the clinical
`
`
`
`
`
`
`
`
`manifestations of CRF and end-stage renal disease (ESRD)
`
`
`
`
`
`
`known as uremia is uncertain, urea levels in the blood are
`
`
`
`
`
`
`
`
`
`commonly used as one measure ofrenal function and the need
`
`
`
`
`
`
`
`
`for and frequency ofrenal replacement therapy such as dialy-
`
`
`
`
`
`
`
`
`sis. As a corollary ofthe findings noted above in UCD patients
`
`
`
`
`
`
`
`(e.g. Brusilow, Pediatric Research, vol. 29, 147-50 (1991);
`
`
`
`
`
`
`
`
`Brusilow and Finkelstien, .1. Metabolism, vol. 42, 1336-39
`
`
`
`
`
`
`
`(1993)), increased waste nitrogen excretion in the form of
`
`
`
`
`
`
`
`PAGN resulting from administration of PAA prodrugs
`
`
`
`
`
`
`
`decreases urea synthesis and therefore can serve as an alter-
`
`
`
`
`
`
`
`
`native to urea excretion. Consistent with this, Brusilow (U.S.
`
`
`
`
`
`
`
`
`Pat. No. 4,284,647) has demonstrated that administration of
`
`
`
`
`
`
`
`sodium benzoate, which increases waste nitrogen excretion in
`
`
`
`
`
`
`
`the form of hippuric acid, lowered blood urea levels in a
`
`
`
`
`
`
`
`
`
`patient with renal failure (FIG. 14). Accordingly, PAA pro-
`
`
`
`
`
`
`
`
`drugs, including PBA and HPN-100 can be used to treat CRF
`
`
`
`
`
`
`
`
`as well as UCDs and HE, and methods for determining and
`
`
`
`
`
`
`
`
`
`adjusting dosage ofthese PAA prodrugs and monitoring treat-
`
`
`
`
`
`
`
`
`ment efficacy are among the inventions disclosed herein. In
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`general, and without being limited by theory, prodrugs of
`PAA which do not contain sodium would be preferred for
`
`
`
`
`
`
`
`
`treatment of treatment of those nitrogen retention states,
`
`
`
`
`
`
`
`
`including CRF as well as cirrhosis and HE, which are also
`
`
`
`
`
`
`
`
`
`known to be associated with sodium and fluid retention mani-
`
`
`
`
`
`
`
`
`fested, for example, as ascites and or peripheral edema. HPN-
`
`
`
`
`
`
`
`
`100 is one such sodium-free PAA prodrug.
`
`
`
`
`
`
`
`DISCLOSURE OF EMBODIMENTS OF THE
`
`
`INVENTION
`
`
`
`
`
`[0021] The invention provides a novel approach for deter-
`
`
`
`
`
`
`
`
`mining and adjusting the schedule and dose of orally admin-
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`istered nitrogen scavenging drugs, including sodium phenyl-
`
`
`
`
`
`butyrate and glyceryl
`tri-[4-phenylbutyrate]
`(HPN-100),
`based upon the urinary excretion of the drug metabolite phe-
`
`
`
`
`
`
`
`
`nylacetylglutarnine (PAGN) and/or total urinary nitrogen. It
`
`
`
`
`
`
`is based in part on the discovery that bioavailability of these
`
`
`
`
`
`
`
`drugs as conventionally assessed based on systemic blood
`
`
`
`
`
`
`levels of the drugs themselves or of the active species pro-
`
`
`
`
`
`
`
`
`
`duced in vivo from these drugs does not accurately predict
`
`
`
`
`
`
`
`
`
`removal ofwaste nitrogen or reduction ofplasma ammonia in
`
`
`
`
`
`
`healthy human volunteers, adults with liver disease, or
`
`
`
`
`
`
`
`
`patients with UCDs receiving ammonia scavenging drugs as
`
`
`
`
`
`
`
`defined below. Conversion of orally administered sodium
`
`
`
`
`
`
`phenylbutyrate (NaPBA, or sodium PBA) to urinary PAGN
`
`
`
`
`
`
`(uPAGN) is now shown to be incomplete: conversion is typi-
`
`
`
`
`
`
`cally about 40-70%, or about 54% on average. (A preliminary
`
`
`
`
`
`
`
`analysis suggested the range would be around 60-75%, but
`
`
`
`
`
`
`
`
`final analysis shows the average is about 54%.) The average
`
`
`
`
`
`
`
`
`
`value of about 54% conversion was determined experimen-
`
`
`
`
`
`
`
`tally for orally administered HPN-100 or PBA converting into
`
`
`
`
`
`
`
`
`urinary PAGN, and a range of about 40-70% represents the
`
`
`
`
`
`
`
`
`average plus or minus approximately one standard deviation
`
`
`
`
`
`
`
`for this data set. By comparison, correlating urinary PAGN
`
`
`
`
`
`
`
`
`
`with drug dosage using information available in the art would
`
`
`
`
`
`
`
`
`
`have provided substantially different results, since the prior
`
`
`
`
`
`
`
`
`art suggests a much higher conversion, e.g., 90% or more. As
`
`
`
`
`
`
`
`
`used in this context, “about 54%” refers to a value between
`
`
`
`
`
`
`
`
`50% and 60%, and the urinary PAGN output refers to a
`
`
`
`
`
`
`
`
`
`
`measure of urinary PAGN output for a subject receiving
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`ongoing stable daily dosages ofthe nitrogen scavenging drug.
`[0022] Urinary PAGN can be measured in various ways; in
`
`
`
`
`
`
`some embodiments, as described herein, it is a 24-hour mea-
`
`
`
`
`
`
`
`surement, which means measurement of total urinary PAGN
`
`
`
`
`
`
`
`
`Page 20 of 48
`
`
`
`US 20l2/0022l57 Al
`
`Jan. 26, 2012
`
`output for a period of 24 hours following the first dose of the
`day of a nitrogen scavenging drug. In other embodiments, a
`12-24 hour urinary PAGN level is used, which is the total
`amount of urinary PAGN excreted over the time period 12-24
`hours after the first dose of the day. As an alternative, as
`described herein, spot testing of urinary PAGN levels can be
`used, by normalizing the value as a ratio to urinary creatinine
`output. Daily creatinine output is relatively stable for most
`subjects, and this has been found to be true even in the UCD,
`HE, and CRF patients receiving the nitrogen scavenging
`drugs described herein. Because creatinine output is rela-
`tively stable, it can be used to normalize urinary PAGN output
`levels: from a ‘spot test’ of a partial sample, the ratio of
`uPAGN to urinary creatinine can be used to estimate a total
`daily urinary PAGN output. These values may be used in
`calculations of dosages or protein intake based on urinary
`PAGN output as well as for determining initial drug dosage
`for a patient taking a given amount of protein.
`[0023] The invention further provides methods to easily
`monitor treated patients to determine from urinary PAGN
`output whether their overall treatment program (diet and
`medication) is working, and when the patient needs a modi-
`fied treatment program or adjusted drug dosage. These meth-
`ods comprise monitoring urinary PAGN output, either as a 24
`hour output, or as a 12-24 hour total urinary PAGN output, or
`as an estimated value from a spot test, where the urinary
`output is normalized to urinary creatinine and converted to an
`estimated 24-hour (or 12-24 hour) output. In one embodi-
`ment, the method comprises comparing that value for urinary
`PAGN to a cut-off value that distinguishes patients likely to
`have normal ammonia levels from patients likely to have high
`ammonia levels.
`
`Prodrugs of phenylbutyrate (PBA, the active ingre-
`[0024]
`dient in BUPHENYL® (sodium phenylbutyrate), which is
`the sodium salt of PBA along with small amounts of inert
`ingredients), which is itself a prodrug of phenylacetic acid
`(PAA), are especially subject to the effects described herein.
`
`CO2'Na+
`
`phenylbutyrate
`OH
`
`O
`
`Phenylacetic acid
`NH;
`
`O
`
`.,,’,/NH
`
`Phenylacetylglutamine
`
`[0025] As used herein “ammonia scavenging drugs” is
`defined to include all orally administered drugs in the class
`which contain or are metabolized to phenylacetate. Thus, the
`
`Page 21 of 48
`
`term includes at least phenylbutyrate, BUPHENYL® (so-
`dium phenylbutyrate), AMMONAPS®, butyroyloxymethyl-
`4-phenylbutyrate, glyceryl
`tri-[4-phenylbutyrate]
`(HPN-
`100), esters, ethers, and acceptable salts, acids and derivatives
`thereof. These drugs reduce high levels of endogenous
`ammonia by providing phenylacetic acid in vivo, which is
`metabolized efiiciently to form phenylacetyl glutamine
`(PAGN). PAGN is efiiciently excreted in urine, carrying away
`two equivalents of nitrogen per mole of PAA converted to
`PAGN. References herein to sodium phenylbutyrate are
`understood to include reference to the drug product BUPHE-
`NYL®, and BUPHENYL® was used for the Examples herein
`wherever test subjects were treated with sodium phenylbu-
`tyrate. Thus the sodium PBA dosages used in the Examples
`generally refer to a dosage of BUPHENYL®, and the
`amounts of sodium phenylbutyrate in those Examples should
`be interpreted accordingly. Note that the terms ‘ammonia
`scavenger’ and ‘nitrogen scavenger’ are used interchangeably
`in this invention, reflecting the fact that the drugs described
`herein lower blood ammonia and/or urea levels through
`elimination of waste nitrogen in the form of PAGN.
`[0026]
`In some embodiments, the invention uses prodrugs
`that can be converted into PAA within the body. Sodium
`phenylbutyrate (sodium PBA) is one such drug; it is converted
`by oxidative mechanisms into PAA in the body. HPN-100 is
`another such dr